Thyroid cancer therapy with lenvatinib mesylate must be paid for by insurance companies from July 3 if radiotherapy and surgery have not been effective
The National Supplementary Health Agency (ANS) announced this Wednesday 31, another update of the list of health procedures and events, the third of this year. Effective July 3, coverage by health plans for lenvatinib mesylate thyroid cancer treatment will be mandatory.
According to the regulatory agency, the drug should be offered on medical advice to patients in whom surgery and radiation therapy have not been effective. The list establishes compulsory care coverage for health plans, which have approximately 50.2 million users in Brazil.
ANS highlighted that the list “represents a milestone for the beneficiaries and for the sustainability of the sector”, since “technologies undergo a process that provides for broad social participation and careful technical analysis”.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
